Unraveling cocaine metabolism in patients with cocaine use disorder for the purpose of potentially improving bioanalytical tests for cocaine use - Unraveling cocaine metabolism in patients with CUD

开始日期2024-11-12

申办/合作机构-

NCT06443255

/ Completed临床3期IIT

Comparison of Cocaine, Lidocaine/xylometazoline and Saline for Intranasal Analgesia - a Blinded Triple Crossover Study

When performed by trained personnel nasotracheal intubation is a safe and effective technique for attaining a secure airway in preparation for surgery of the head and neck. The procedure can be deemed necessary due to the nature of the surgical procedure or considerations in regard to the patient's comorbidities. For a certain group of patients with expected difficult airways, the procedure is done whilst they are awake and aided by fiberoptics.
For these awake patients, extra precautions must be taken to ensure the procedure is conducted with minimal pain and discomfort. The pain and discomfort arises from the mechanical manipulation of the nasal mucosa and can be alleviated in part by means of topical analgesia as well as through decongestion, providing more space within the nasal cavity. For these purposes, several drugs in varying combinations and dosages are used, but no single drug choice is universally recommended.
Cocaine is one of these appropriate drugs. It is a magistral formula used especially due to its unique combination of both vasoconstrictive and analgesic properties. Concerns have though been raised regarding cocaine's potential toxicity and alternative medications are continuously sought after.
A combination of lidocaine and xylometazoline can also be used for preparation of the nose prior to awake nasal fiberoptic intubation. Lidocaine contributes with its analgesic effect whilst xylometazoline functions as the vasoconstrictor.
The investigators wish to compare the analgesic effects of cocaine and lidocaine/phenylephrine to each other and saline when subjectively scored on a visual analogue scale of 0-100 mm immediately after simulated awake nasal intubation on healthy volunteers.

开始日期2024-07-01

申办/合作机构

Rigshospitalet

NCT05809453

/ Completed临床1/2期IIT

Intranasal Cocaine and Temperature Regulation During Exercise

Assess the effects of intranasal cocaine on temperature regulation and whole-body sweat rate during exercise in warm environmental conditions.

开始日期2023-09-01

申办/合作机构

The University of Texas Southwestern Medical Center

100 项与盐酸可卡因相关的临床结果

登录后查看更多信息

100 项与盐酸可卡因相关的转化医学

登录后查看更多信息

100 项与盐酸可卡因相关的专利（医药）

登录后查看更多信息

49,571

项与盐酸可卡因相关的文献（医药）

2025-08-01·Brain, Behavior, and Immunity

Activation of Nuclear Factor-kappa B in the nucleus accumbens core is necessary for chronic stress-induced glutamate and neuro-immune alterations that facilitate cocaine self-administration

Article

作者: Rigoni, Diana ; Cancela, Liliana Marina ; Guzman, Andrea Susana ; Mongi-Bragato, Bethania ; Bisbal, Mariano ; Boezio, María Julieta ; Bollati, Flavia Andrea ; Perassi, Eduardo Marcelo ; Mas, Carlos Ruben ; Sánchez, Marianela Adela ; Avalos, María Paula

Stressful events are associated with impaired glutamate signaling and neuroimmune adaptations that may increase the vulnerability of individuals to cocaine addiction. We previously demonstrated that chronic stress induced reactive microglia and increased TNF-α expression in the nucleus accumbens core (NAcore), both alterations strongly linked with impaired glutamate homeostasis and the facilitation of cocaine self-administration. The nuclear factor kappa-B (NF-κB) is a critical regulator of many immune- and addiction-related genes, such as the gene coding for glutamate transporter (GLT-1), and it is considered a master regulator of inflammation, reported to be a key driver of microglia activation in psychiatric diseases. However, no studies have examined the role of NF-κB signaling within the NAcore in the neuroimmune and glutamate mechanism, underpinning stress-induced vulnerability to cocaine self-administration. Here we investigate whether viral dominant negative inhibition of I kappa B kinase (IKKdn), a signaling molecule responsible for NF-κB activation, would prevent stress-induced facilitation to cocaine self-administration and associated changes in accumbal GLT-1 and TNF-α expression. We also explore N-myc proto-oncogene protein (N-myc) levels as a link between NF-κB and stress-induced GLT-1 downregulation. For seven days (days 1-7), adult male rats were restrained for 2 h/day. Animals were administered an intra-NAcore with IKKdn or empty lentiviruses on day 14 after the first restraint stress session. Marked activation of NF-κB was detected in the NAcore of stressed subjects, along with increased NF-κB expression in astrocytes. Consistently, viral NF-κB inhibition prevented stress-induced facilitation of cocaine self-administration. Moreover, NF-κB blockade results in the restoration of stress-induced reduction in GLT-1 levels and was effective in suppressing stress-induced TNF-α within the NAcore. These findings suggest that accumbal NF-κB signaling exerts a central control over stress-altered downstream neuroimmune and glutamate function underlying vulnerability to cocaine use disorders.

2025-08-01·Neuropharmacology

Sex-dependent role of the dorsolateral septum in shaping contextual cocaine memory strength

Article

作者: Soto, D A ; Fuchs, R A ; Reeves, D A ; Pruitt, A Y ; Ritchie, J L ; Artimenia, L M ; Qi, S

Established memories can be destabilized, updated, and reconsolidated into long-term memory stores. Memory updating and reconsolidation can alter the strength of maladaptive contextual drug memories and consequently context-induced drug craving and relapse. The dorsolateral septum (dlS) is a GABAergic nucleus that receives dense direct input from the cornu ammonis 3 regions of the dorsal hippocampus, a brain region that is critical for the maintenance of contextual cocaine memories. Accordingly, we tested the hypothesis that neuronal activity in the dlS regulates the strength of cocaine-predictive contextual memories prior to reconsolidation. Male and female Sprague-Dawley rats received cocaine self-administration training followed by extinction training in two different environmental contexts. After the last extinction training session, the rats were placed back into the cocaine-predictive context to retrieve and destabilize their cocaine-related contextual memories. Immediately or 6 h after memory retrieval, the rats received intra-dlS vehicle or baclofen/muscimol (B/M; GABA_B/A agonists) infusions to inhibit neuronal activity during or after memory updating/reconsolidation, respectively. Resulting changes in cocaine and extinction memory strength were assessed based on the magnitude of unreinforced lever responding in the two contexts. Intra-dlS B/M infusion immediately after memory retrieval increased subsequent context-induced cocaine seeking behaviors in male rats, but not in female rats, whereas delayed B/M treatment had no effects in male rats. Together these findings suggest that the dlS is selectively engaged during memory updating/reconsolidation to reduce the strength of cocaine memories in males, possibly contributing to sex differences in the progression of cocaine use disorder.

2025-08-01·Journal of Affective Disorders

Cannabis and tobacco use in bipolar disorder: Associations with early onset, psychotic symptoms, and relapse risk (2015-2019)

Article

作者: de Juan, Oscar ; Vieta, Eduard ; Pacchiarotti, Isabella ; Giménez-Palomo, Anna ; Salmerón, Sergi ; Fernández-Plaza, Tábatha ; Ochandiano, Iñaki ; Olivier, Luis ; Colomer, Lluc ; Andreu, Helena

BACKGROUNDSubstance use disorders (SUD) frequently occur alongside bipolar disorder (BD), with some studies indicating a 29 % comorbidity rate in Western populations [1]. The relationship between BD and SUD is intricate and bidirectional - drug misuse can increase the risk of developing BD, and individuals with BD have a higher risk of developing SUD. This complex interplay often leads to earlier BD onset, more hospitalizations, and reduced effectiveness of pharmacological treatments, particularly mood stabilizers. This work aims to describe the impact of drugs in the risk of relapse in BD and to approach the differences in the evolution in substance users compared to non-users.METHODSWe conducted a prospective cohort study including the patients admitted to Hospital Clínic of Barcelona acute psychiatric unit with the diagnosis of manic or mixed episode during the period between 2015 and 2019. We established a follow-up of 3 years from the date of admission in which hospital readmissions are examined.RESULTSThe study, which included 279 patients, concluded that only tobacco users showed significantly higher rates of emergency room (ER) visits and hospital readmissions in the period study, while cannabis was only associated with earlier onset of illness, current manic polarity, the presence of psychotic symptoms and a higher likelihood of discontinuing treatment. Alcohol, cocaine and stimulants did not appear to have an association with the variables studied.LIMITATIONSLack of follow-up information from people leaving the region or changing to private sector services, lack of detailed information around the pattern and history of consumption.CONCLUSIONSTobacco seemed to have a clear negative association with the course of the illness. Cannabis, while its use was not associated with the relapse rate, was indirectly associated with variables suggesting a more severe symptomatology and a possible qualitatively different course of illness. More evidence is needed to define the mechanisms and patterns related to these effects.

264

项与盐酸可卡因相关的新闻（医药）

2025-04-22

·GlobeNewswire-Health Care

Intelligent Bio Solutions Expands Global Reach with Latin American Spanish Language Integration into Drug Screening System

Company expands Intelligent Fingerprinting Drug Screening System multilingual capabilities to meet growing demand across Latin American Spanish-speaking markets Latin American drug screening market projected to reach USD 1.1 billion by 2030 Expansion is part of major multilingual Drug Screening System upgrade, targeting over 4 billion potential users worldwide NEW YORK, April 22, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the integration of Latin American Spanish into its Intelligent Fingerprinting Drug Screening System (the “System”). The enhancement allows users to operate the System in English, Arabic, and Latin American Spanish, extending the platform’s usability across diverse, international settings. Spanish is the fourth most spoken language in the world and the second most spoken language in the U.S. It is the official language in over 20 countries, including the majority of countries in Latin America, and is spoken by over 500 million people globally1. By incorporating Latin American Spanish into the System, INBS strengthens its support for Spanish-speaking markets and regional distribution partners. This update increases accessibility for end-users across North America, Central America, South America, and Europe, aligning with the Company’s strategic growth plans. “As we see increased interest from Spanish-speaking distributors and companies, we must ensure our solution remains accessible and relevant to these markets. Integrating Latin American Spanish into our System is a key step toward opening new opportunities for future growth,” said Harry Simeonidis, President & CEO at Intelligent Bio Solutions. “As demand grows, so does the value of business localization. Our product stands out in the market by offering local language capabilities, something most solutions don’t provide. It’s a clear differentiator.” The Latin American drug screening market is projected to reach USD 1.1 billion by 2030, driven by increasing public safety initiatives and growing demand for workplace compliance programs2. In Europe, Spain’s drug testing market is expected to reach USD 368.4 million by 20303, reflecting similar trends in regulation and adoption. INBS’ multilingual capabilities position the Company to better serve evolving testing needs through an intuitive, localized platform experience. This development forms part of the Company’s major multilingual system upgrade announced earlier this year. The complete multilingual upgrade will support multiple languages spoken across the Americas, Europe, Asia Pacific and the Middle East, making the System accessible to over 4 billion speakers worldwide4. The added capability supports a broader growth strategy to expand on a foundation of over 400 accounts across 19 countries and to penetrate new markets and regions. The Latin American Spanish enhancement is a key development milestone as the Company prepares to enter the multi-billion-dollar U.S. market this year, following its FDA 510(k) submission in December 2024. About Intelligent Bio Solutions Inc. Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners. For more information, visit: http://www.ibs.inc/ Forward-Looking Statements Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. Company Contact:   Intelligent Bio Solutions Inc.  info@ibs.inc   LinkedIn | Twitter  Investor & Media Contact: Valter Pinto, Managing Director KCSA Strategic Communications PH: (212) 896-1254 INBS@kcsa.com _____________________________ Hyperlinks and website references in this release are provided for convenience only, and do not incorporate the referenced content into this release. 1 Statista 2025. Countries with the largest number of native Spanish speakers worldwide in 2024. Available at: https://www.statista.com/statistics/991020/number-native-spanish-speakers-country-worldwide/ 2 Grand View Research 2025. Latin America Drug Screening Market Size & Outlook. Available at: https://www.grandviewresearch.com/horizon/outlook/drug-screening-market/latin-america3 Grand View Research 2025. Spain Drug Screening Market Size & Outlook, 2018-2030. Available at: https://www.grandviewresearch.com/horizon/outlook/drug-screening-market/spain 4 Ethnologue, 2024. The Ethnologue 200. Available at: https://www.ethnologue.com/insights/ethnologue200/

2025-04-17

·PRNewswire

Prominent Psychiatrist Introduces Breakthrough Treatment for Addiction

NEW YORK, April 17, 2025 /PRNewswire/ -- Dr. DiFrancesco () is deeply enthusiastic about new developments in the treatment of addiction and has launched a new website for individuals who would like to learn more and are seeking treatment. Experience the full interactive Multichannel News Release here: Continue Reading Dr. Eileen DiFrancesco Introduces Breakthrough Treatment For Addiction Dr. Eileen DiFrancesco Introduces Breakthrough Treatment For Addiction Dr. Eileen DiFrancesco a physician in New York City has specialized in Psychiatry and Psychopharmacology for over two decades treating a wide variety of neuropsychiatric disorders, focusing on addiction. She has had the opportunity to train in Ivy League schools and work in the ivory towers of Medicine, but unfortunately, she says there has never been an effective medication for the treatment of addiction - until now. Patients who are taking the popular drug Ozempic, also known as semaglutide which was developed for the treatment of diabetes and weight loss are experiencing remarkable results. Surprisingly, they are not only reporting a decrease in the over consumption of food, but also little or no interest in alcohol. DiFrancesco says this is not a coincidence or a side effect. As published in JAMA, Nature and Science Direct -these medications target neural circuits involved in reward and satiety and therefore greatly curb craving for addictive substances. Semaglutide and a similar medication tirzepatidetide are medication's that mimic a natural hormone called glucagon -like peptide – 1 or GLP -1. These hormones are activated when the GLP one receptor agonist attached to their receptors. What is truly exciting is that GLP one receptors are all over the brain reward pathway. This pathway exists to provide a sense of pleasure or reward when we do something that is essential for our survival or survival of the species such as eating healthy foods having sex and nurturing relationship relationships. The reward or sense of pleasure is intended to make us repeat these behaviors so that our species will survive because we eat well, procreate and take care of others. However, substances and things that are highly pleasurable can take over these reward circuits. This causes the natural rewards to become less pleasurable and even ignored. This is what addictive substances do, they hijack the reward pathway in such a way that they become the focus of an individual's life. According to JAMA, a nationwide register based study with GLP one receptor agonist Semaglutide were associated with a markedly, reduced risk of alcohol use disorders and substance use disorder related hospitalizations. In the journal nature, the administration of GLP one has convincingly shown to reduce alcohol intake and pre-clinical models. Observational studies clearly show that GLP one receptor Agnes are associated with non-volitional reduction and the use of alcohol, nicotine, cocaine and opioids. When GLP one receptor agonist activate the GLP one receptors in the reward pathway, the sense of reward from the addictive substances, including alcohol, nicotine cocaine, and even opioid becomes less rewarding. This serendipitous finding is truly amazing and wonderful. When combined with already existing treatment for addiction, DiFrancesco Psychiatry feels there is finally help and hope for treating this destructive and debilitating disease. If you or someone you love is suffering and would like to learn more, please contact us at: [email protected]. About Dr. Eileen DiFrancesco Dr. Eileen DiFrancesco graduated with honors from the University of Pennsylvania where she received her Bachelor's Degree. After earning a medical degree from Temple University School of Medicine, she received additional training in both Psychiatry and Neurology. Upon completing residency training at Mount Sinai Medical Center in New York City she was appointed Medical Director of the Learning Laboratory, a private facility in Connecticut. There she specialized in diagnosing and treating Attention Deficit Disorder, Addiction, Depression and Bipolar Disorder, using Quantitative EEG also known as Brain Mapping. Her diagnostic skills were also utilized at the Mount Sinai School of Medicine where she assessed psychotic adolescents for Schizophrenia treatment and eligibility for research protocols. SOURCE xsrxdoctor WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2025-04-10

·PRNewswire

Newborn Brains Are Smaller When Exposed to Opioids During Gestation

An important "first dive" into data from the 4-site Outcomes of Babies with Opioid Exposure (OBOE) study features a Cincinnati Children's expert as co-first author CINCINNATI, April 10, 2025 /PRNewswire/ -- When pregnant women take opioids during pregnancy, even opioids such as buprenorphine or methadone to treat opioid use disorder, the developing brains of their children can be significantly affected, according to a study published April 7, 2025, in JAMA Pediatrics. Continue Reading Antenatal opioid exposure is associated with smaller neonatal brain volumes, with varying impact depending on the type and number of exposures, according to research published in JAMA Pediatrics. Stephanie Merhar, MD, MS, at Cincinnati Children's was first co-author. Total brain volume was nearly 5% smaller among 173 newborns with antenatal opioid exposure compared to 96 unexposed newborns, based on magnetic resonance imaging (MRI) scans. More specifically, reduced volumes among opioid-exposed newborns occurred in cortical gray matter, deep gray matter, white matter, cerebellum, brainstem, and the right and left amygdala. There were notable differences in the location and scale of the effects, which varied depending on the type of opioid involved, and whether other drugs were also taken during pregnancy. "We have known for a while that children exposed to opioids during pregnancy are at risk of later developmental and behavioral problems, but it was hard to know whether that was due to the opioids themselves or other factors such as other exposures or lower birth weight," says co-first author Stephanie Merhar, MD, MS, a neonatologist at Cincinnati Children's. "This study was launched because we needed a large study where we were able to control for things like nicotine exposure and birth weight. Our next step is to follow the children in the study to see whether having smaller brain volumes in the newborn period affects later development and behavior." The double-threat opioids pose to mothers and children Nearly 1 in 12 newborns in the United States in 2020 – or about 300,000 infants – were exposed to alcohol, opioids, marijuana or cocaine before they were born, according to the Substance Abuse and Mental Health Services Administration (SAMHSA). Prenatal substance exposure in rural areas often exceeds overall national averages. Opioids include illegal drugs like heroin and fentanyl, prescription drugs like oxycodone and hydrocodone, and medications for opioid use disorder like buprenorphine and methadone. Opioid use often goes hand in hand with smoking and use of other substances such as alcohol and marijuana. This study compared newborns born to mothers who took opioids only and newborns born to mothers who used other substances as well as opioids. Newborns exposed to opioids plus other substances had smaller brain volumes in more regions compared to those exposed to opioids only. The most common opioids among participants in the new study were buprenorphine (68.8%) and methadone (26%). Both of these opioids are routinely used to treat opioid use disorder (OUD) and are both recommended for treatment of OUD during pregnancy by the American College of Obstetricians and Gynecologists. "We know that buprenorphine and methadone are life-saving medications for women with OUD," Merhar says. "We don't want to imply that women with OUD should wean off these medications, but we agree with the ACOG recommendation for more research on medically supervised withdrawal in pregnant women." The study was praised in an accompanying editorial penned by Nethra Madurai, MD, and Lauren Jantzie, PhD, both of Johns Hopkins University School of Medicine. Other small studies have shown fetal brain changes caused by opioids. But this multi-center study is the first to be large enough to convincingly distinguish effects linked to opioids versus confounding factors such as maternal smoking, birth weight, education levels. The study authors "present compelling evidence of the direct effects of opioids on the developing brain," the editorial states. "Given the prospective design of the trial, they account for other postnatal factors…allowing us to dispel previous uncertainty surrounding the direct impacts of opioids on the brain vs the confounding effects of other environmental factors." What's next? Having more precise information about the affected parts of the brain could allow scientists to focus on interventions to support healthy brain development for children born after opioid exposure. "Indeed, we must shift our focus beyond the initial withdrawal symptoms associated with POE [prenatal opioid exposure] if we are to improve the lifelong health and well-being of infants and children impacted by the opioid epidemic," the editorial states. Read more about Merhar's research related to opioid exposure: 'Eat, Sleep, Console' Approach Slashes ICU Stays for Opioid-Exposed Newborns In Utero Opioid Exposure Impacts Fetal Brain Size and Development $8M Grant Funds Long-Term Opioid Exposure Study SOURCE Cincinnati Children's Hospital Medical Center WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

100 项与盐酸可卡因相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02182	盐酸可卡因	S01HA01 S02DA02 N01BC01 R02AD03	DB00907

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
麻醉	美国	Noden Pharma DAC	2017-12-14

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
可卡因相关疾病	药物发现	美国	Biotie Therapies Oy	2008-06-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ATS2024	N/A	筋膜间隔综合征 \| 高钾血症	-	Cocaine	願範鬱顧淵觸網顧鹽鹽(鬱觸淵鑰廠夢窪壓網鑰) = showed a Wellens' pattern with ST-elevation and biphasic T-waves in lead V2-V3 窪襯選鬱艱鑰窪齋鏇鬱 (遞網鬱齋夢選願築衊膚 ) 更多	-	2024-05-19
ATS2023	N/A	毛细支气管炎	-	Cocaine	糧艱獵廠鹹鑰醖夢構積(獵鹹淵廠鹹餘鏇鏇憲鹹) = 膚鏇鹹網窪製鹽壓衊積醖憲製夢積範憲廠積顧 (鬱鹹繭蓋遞窪襯選憲製 ) 更多	-	2023-05-21
NCT01906346 (CTgov)	早期临床1期	可卡因相关疾病	9	Placebo+Cocaine (Low Value Alternative Reinforcer)	網憲構築簾糧鑰選獵構(醖觸鑰膚鹹齋製壓鏇窪) = 製願膚觸蓋構範憲糧蓋鑰壓襯遞構觸糧鹹衊範 (製簾蓋選淵觸鏇鏇齋艱, 網簾顧範膚艱繭膚範淵 ~ 簾構夢簾衊願積夢憲糧) 更多	-	2019-05-17
				Placebo+Cocaine (Medium Value Reinforcer)	網憲構築簾糧鑰選獵構(醖觸鑰膚鹹齋製壓鏇窪) = 觸網醖淵積夢顧糧壓鏇鑰壓襯遞構觸糧鹹衊範 (製簾蓋選淵觸鏇鏇齋艱, 願鹹願鑰鹽齋鏇獵壓艱 ~ 獵鏇願壓積齋積衊衊衊) 更多
NCT02383043 (CTgov)	早期临床1期	可卡因相关疾病	18	Cocaine+Sustained Release d-Amphetamine	夢積獵廠製餘鏇壓糧憲(壓憲顧簾鬱願鬱構蓋蓋) = 艱鏇積積廠襯構壓衊窪選壓膚艱鹽膚鹹鹹觸選 (獵鬱網範襯鏇觸選淵憲, 夢膚繭齋鏇憲淵鹽膚鏇 ~ 鑰壓積構簾鹹獵願簾網) 更多	-	2019-04-11
SFN2018	N/A	可卡因相关疾病	-	Cocaine self-administration	範醖襯遞鹽糧醖壓鏇齋(壓鬱願膚鬱構蓋遞遞構) = 艱衊齋網遞簾糧壓簾築糧築襯顧鹹憲網繭築膚 (鹽獵鑰衊夢艱鏇獵網選 )	-	2018-11-06
AAN2018	N/A	急性缺血性卒中 cocaine use	-	AIS with cocaine use	鑰遞顧壓鹹遞夢壓築鹹(願範積遞構廠糧淵餘範) = 襯鬱觸膚壓蓋構蓋獵壓範餘鬱蓋窪製構鹹廠積 (網鏇遞獵壓簾製鹽淵壓 ) 更多	-	2018-04-10
				AIS without cocaine use	鑰遞顧壓鹹遞夢壓築鹹(願範積遞構廠糧淵餘範) = 廠窪顧餘蓋鏇鹽夢夢齋範餘鬱蓋窪製構鹹廠積 (網鏇遞獵壓簾製鹽淵壓 ) 更多
ACR2017	N/A	抗中性粒细胞胞质抗体相关性血管炎 ANCA antibodies \| inflammatory markers \| haematology and biochemistry profiles	14	Cocaine-induced vasculitis	夢醖顧憲齋願鹽積積遞(艱鬱鏇構齋積窪膚範艱) = 鹽齋壓繭艱夢憲餘衊鑰蓋簾簾齋糧網鏇鏇衊膚 (鹹範夢鏇築艱遞糧願齋 ) 更多	不佳	2017-11-06
				Cocaine (Idiopathic ANCA vasculitis)	夢醖顧憲齋願鹽積積遞(艱鬱鏇構齋積窪膚範艱) = 網鬱壓襯憲齋憲簾醖積蓋簾簾齋糧網鏇鏇衊膚 (鹹範夢鏇築艱遞糧願齋 )
NCT00373880 (CTgov)	临床2期	可卡因相关疾病	26	Placebo+Cocaine (Placebo + 0mg Cocaine)	觸製鏇憲獵廠簾膚艱鹽(鬱蓋顧網選範淵蓋醖選) = 顧廠鹽窪願壓築衊窪選窪膚鏇範觸窪艱憲淵窪 (襯網淵獵鑰醖艱鑰鏇遞, 顧壓遞構獵顧醖觸窪衊 ~ 艱鏇簾積膚簾醖廠淵遞) 更多	-	2017-09-11
				Placebo+Cocaine (Placebo + 12mg Cocaine)	觸製鏇憲獵廠簾膚艱鹽(鬱蓋顧網選範淵蓋醖選) = 齋築艱選壓蓋夢醖願築窪膚鏇範觸窪艱憲淵窪 (襯網淵獵鑰醖艱鑰鏇遞, 蓋鬱網艱廠簾齋衊築糧 ~ 襯網遞衊衊蓋鹹網糧簾) 更多
NCT01706952 (CTgov)	临床4期	慢性鼻窦炎	45	Cocaine+adrenaline (Cocaine)	餘遞製願膚遞廠窪顧窪(構鹹遞艱觸製窪願築鬱) = 壓範獵衊憲憲衊構構襯蓋齋範壓網構衊鏇鏇顧 (獵繭淵憲膚蓋膚顧衊鬱, 壓選範糧築簾齋蓋艱構 ~ 遞繭糧齋鹽醖顧範蓋鹹) 更多	-	2017-05-03
				Cocaine+adrenaline (Adrenaline)	餘遞製願膚遞廠窪顧窪(構鹹遞艱觸製窪願築鬱) = 衊鏇遞艱觸願壓鏇範鹹蓋齋範壓網構衊鏇鏇顧 (獵繭淵憲膚蓋膚顧衊鬱, 鬱積製鏇糧製醖廠壓壓 ~ 醖壓糧夢網醖簾鹹鹹艱) 更多
SFN2016	N/A	-	-	intravenous cocaine (5s-Rats)	鑰顧觸鹹餘蓋夢醖繭願(襯夢繭網獵衊鏇獵鏇餘) = 構餘鑰齋繭範艱壓膚淵選範鹽鬱壓鹹壓構鹽簾 (艱築積夢淵糧淵遞範獵 )	-	2016-11-16
				intravenous cocaine (90s-Rats)	鑰顧觸鹹餘蓋夢醖繭願(襯夢繭網獵衊鏇獵鏇餘) = 淵鏇艱艱獵簾齋窪製糧選範鹽鬱壓鹹壓構鹽簾 (艱築積夢淵糧淵遞範獵 )